set by the Bulgarian Institute for Standardization. Some of the companies that are already working with Lactina starter cultures and whose products are on the market are DANONE Serdica (DANONE Group) and Domlyan. Apart from these two companies, Lactina Ltd. is currently collaborating with OMC (United Milk Company) and Mlechen Rai (Milky Paradise company), which are soon expected to launch on the market yoghurt according to the new Bulgarian standard again with starters from Lactina.hide news
Lactina Ltd. has been approved as a supplier of starter cultures for Bulgarian yoghurt according to the new standard for Bulgarian yoghurt (BDS 12:2010) set by the Bulgarian Institute for Standardization. Some of the companies that are already working with Lactina starter cultures and whose products are on the market are DANONE Serdica (DANONE Group) and Domlyan. Apart from these two companies, Lactina Ltd. is currently collaborating with OMC (United Milk Company) and Mlechen Rai (Milky Paradise company), which are soon expected to launch on the market yoghurt according to the new Bulgarian standard again with starters from Lactina.hide news
Lactina Ltd. participated with a poster presentation at the International Scientific Conference on Probiotics and Prebiotics - IPC 2010 held 15th-17th june 2010 in the city of Kosice, Slovakia.hide news
Lactina Ltd has been recertified for its GMP (Good Manufacturing Practice) and ISO 22000:2005 (Food Safety Management System) during a recent audit by the United Registrar of Systems Ltd., Bulgaria (URS). These certificates indicate that the company conforms to internationally set production standards in every aspect of its operations and takes proactive steps to ensure that its products are safe, pure, and effective.hide news
Rose Joghurt for sale in Japan Nakagaki Ltd. starts with sales of Lactina freeze-dried culture with original Bulgarian Lactobacillus bulgaricus, Streptococcus thermophilus and Rosa damascenahide news
Evalutaion of Most Probable Numbers Approach for Determination of Lactic Acid Bacteria Cell Counts in Synbiotic Preparation Actiflora®.
Grozdanov, L., Karaivanova, E. and Rumyan, N.
Research and Development Department, Lactina Ltd., Bankya, Bulgaria
In this study application of most probable numbers (MPN) approach as rapid, reproduclible and reliable method for routine determination of total viable lactic acid bacteria cell counts in synbiotic Actiflora (Lactobacilus acidophilus, Lactibacillus delbrueckii ssp. bulgaricus, Streptococcus thermophilus, Bifidobacterium spp.) was evaluated. Cultivation of samples from various batches probiotic preparation was performed in 10% reconstituted dry skimmed milk supplemented with 0,5% (w/v ) yeast extract, as well as in parallel on MRS, TPY and M17 agar plates. A confidence coefficent from numerous experiments was calculated and verified. The results indicate that the MPN approach is applicable, cost-effective and time-saving method for routine microbiological screening of probiotic preparations based on lactic acid bacteria.hide news
Lactina Ltd. in co-operation with Nakagaki Consulting Engineer & Co., Ltd. (http://nakagaki.co.jp/rose.html) developed new starter culture for home-made Bulgarian yoghurt with rose blossoms and launch it on the Japanese market.hide news
Intensive clinical studies using Actiflora® capsules are being conducted at the Department of Gastroenterology, “St. Ivan Rilsky“ University Hospital, Sofia, Bulgaria (Nikolov and Krastev, International Journal of Probiotics and Prebiotics, 2008, vol. 3(2):107-110; Nikolov and Krastev, poster presentation at the International Yakult Symposium “The Gut, Immune Modulation and Probiotics”, Verona, Italy, November 22nd – 23rd 2007). The results demonstrate that Actiflora® is well tolerated and contributes to the regulation of the intestinal bacterial ecosystem.
Intestinal saccharolytic fermentation modified by Lactobacillus delbrueckii subsp. bulgaricus and Streptococcus thermophillus. International Journal of Probiotics and Prebiotics, vol 3(2): 107 - 110.
OBJECTIVE: To monitor the intestinal anaerobic saccharolytic fermentation using hydrogen-breath test (HBT) before and after the intake of the synbiotic Actiflora, containing Lactobacillus bulgaricus and Streptococcus thermophillus.
METHODS: 54 Bulgarians without severe organic disease (26 m / 28 f; age 32.9 ± 10.18) were tested: 37 had no complaints, 17 had some long-term functional abdominal complaints, slightly impairing their daily activity (7 reported obstipation, 5 some food intolerance, 4 functional dyspepsia, 1 had both functional dyspepsia and obstipation). All persons received orally synbiotic 3x90 billion colony-forming units daily for 1 week. A clinical assessment and HBT were followed-up.
RESULTS: Initially 18 persons had increased HBT – 25% (9/37) of the people without complaints and 50% (9/17) - with complaints.
After the 7-day course 24/54 remained stable within baseline HBT (low, normal and high; 14/54 normalized HBT; in 1 person from each group there was a decrease in HBT below normal values; 14/54 increased HBT. A clinical improvement was established in 16/17 with complaints, as 4/9 of them with high HBT normalized hydrogen levels.
CONCLUSIONS: The 7-day course with Actiflora was well tolerated and contributed to the regulation of the gut ecosystem, measured by HBT; the slight functional abdominal complaints were improved. The intake of Actiflora was useful both in low and high levels of expired hydrogen.
International Yakult Symposium 2007
The Gut, Immune Modulation and Probiotics
Palazzo della Gran Guardia, Piazza Bra, 37121 Verona.
November 22nd - 23rd 2007
Hydrogen-breath test evaluation of the alterations in the intestinal anaerobic saccharolytic fermentation after the use of a synbiotic.
P. Nikolov*, Z. Krastev*
*Department of Gastroenterology, St. Ivan Rilsky University Hospital, Sofia, Bulgaria.;
Contact author: Dr. P. Nikolov, email@example.com
Aim: To monitor the intestinal anaerobic saccharolytic fermentation using hydrogen-breath test (HBT) before and after the application of the synbiotic Actiflora, containing Lactobacillus bulgaricus, Streptococcus thermophillus, pectin, inulin, etc. in the healthy Bulgarian population. In humans the intestinal bacterial anaerobic saccharolytic fermentation is the only source of hydrogen in the expired air. Methods: Fifty-four Bulgarians without severe organic disease (26 m / 28 f; mean age 32.9 ± 10.18) were tested. Thirty-seven individuals had no complaints. Seventeen persons had some long-term functional abdominal complaints, slightly impairing their daily activity: 6 persons had obstipation, 5 some food intolerance, 5 functional dyspepsia, 1 had both functional dyspepsia and obstipation. All persons received orally synbiotic 3 times daily at a single dosage of 90 billion CFU for 7 days. A clinical assessment and a HBT were followed-up. Results: Initially 18 persons had increased HBT values (9 with abdominal complaints), 11 decreased (1 with complaints) and 25 (7 with complaints) normal. After 7-day course 12/18 with higher HBT showed normal values; 4/11 with decreased HBT had an increase; 12/25 with normal HBT showed an increase and only 1/25 had a decrease. A clinical improvement was established in 16/17 persons with complaints. The adverse effects (transient 1-day diarrhea in 4, flatus in 3) were negligible. Conclusions: The 7-day course with Actiflora was well tolerated and contributed to the regulation of the intestinal bacterial ecosystem, measured by HBT; the slight functional abdominal complaints were improved. The intake of Actiflora was helpful both in low and high levels of expired hydrogen.
In addition, results from ongoing clinical trials conducted at the Faculty of Dental Medicine, Medical University of Sofia indicate that Actiflora® exhibits profound immunostimulatory effect in the human oral cavity (Panov, V, Krasteva, A, Baleva, M, Krastev, Z. Secretory IgA in oral intake of tablets Actiflora. Problems of Dentistry. 2007. XXXIII:32-37). The levels of secretory IgA in the saliva were determined in 10 patients for period of 15 days. The reception of chewable Actiflora® tablets resulted in increased secretion of IgA in the human saliva, which might have a highly protective influence on the human health due to improvement of the local immune defense. This finding is supported by previous studies. Unspecific immune response and gut mucosal immunostimulation after administration of fermented milk and LAB, manifested in increase in the percentage of phagocytosis and number of IgA+ cells in the small intestine, has already been reported (Medici et al., 2005; Vitiñi et al., 2000). Moreover, increase in the number of IgA+ cells on the mucosa surface of the lower respiratory tract induced by oral administration of LAB was observed and proposed to prevent bronchus diseases (Perdigon et al., 1999). It is tempting to speculate that the above reported increase of IgA concentrations in the saliva might exhibit similar beneficial effects and therefore additional clinical trials with Actiflora® tablets are in progress.
SECRETORY IGA IN ORAL INTAKE OF TABLETS ACTIFLORA
Vl. Panov*, A. Krasteva**, M. Baleva***, Z. Krastev***
*Bulgarian Academy of Science, Sofia
**Faculty of Dental Medicine, Sofia
***Medical University, Sofia
The saliva can be easily collected with non-invasive methods. This material consists many components, which is of interest for screening, diagnostics and monitoring of many dieseases. In the last 40 years, many studies show that there is a correlation between the serum and saliva levels of different parameters.
The local treatment with probiotics can modify the oral ecosystem and thus, to affect the immune system. The aim of this study is to investigate the alterations in sIgA in saliva after local oral intake of tablets Actiflora®. The results of this pilot study show that the intake of tablets with Lb. bulgaricus and Str. thermophilus increase the level of sIgA, which probably reflects to the improvement in the immune system.hide news
Lactina organised a conference of Bulgarian dairy prodicers (03 - 04.04.2009, Bankya, Bulgaria).
During seminar program the modern trends in dairy biotechnology, microbiological control and healthy aspects of dairy products were presented and discussed.
1. Development of novel healthy fermented dairy foods - current approach for nutrition and dietetic. Prof. Z. Kounev, Ph.D. University of Oregon, USA.
2. Microbiological control - a basis for production of competitive, high-quality dairy products. Prof. R. Enikova, M. D. National Center of Public Health Protection, Sofia, Bulgaria.
3. Modern directions for elaboration and application of dairy starter cultures. Assoc. Prof. N. Rumyan, Ph. D. Lactina Ltd.
Visitation of Lactina Ltd. production facilities and R&D department. Introduction to technological novelties and new product list.
Taxonomy and in vitro probiotic potential of novel Lactobacillus isolates
1Grozdanov, L., 1Karaivanova, E., 2Dobrindt, U. and 1Rumyan, N.
1 Research and Development Department, Lactina Ltd., Bankya, Bulgaria
2 Institute for Molecular Biology of Infectious Diseases, Bayerische Julius-Maximilians Universitaet, Wuerzburg, Germany
In this study six Lactobacillus strains, isolated either from whey, home-made dairy products or plants were identified and characterized for probiotic application. A phylogenetic three based on 16S rDNA sequences was constructed in order to determine their taxonomic affiliation. Biochemical profiling and analysis of the produced lactic acid isomers were consistent with the 16S sequence analysis, and consequently three of the isolates were appertained to Lactobacillus delbrueckii ssp. bulgaricus (N7, Seven Rila Lakes, KZ) and three to Lactobacillus helveticus (N11, N12, AFA). An in vitro methodology which mimics in vivo human upper gastrointestinal transit was used for evaluation of the potential for probiotic application. The growth in presence of bile salts as well as survival rate of cell suspensions exposed to simulated gastric and small intestine juice were determined. The results indicate that strains belonging to both species are able to persist in the gastrointestinal tract and therefore might induce beneficial effects to the host. In addition, in order to determine the potential for reduction of the risk of gastrointestinal and urogenital disorders, the isolates were tested for production of antimicrobial substances against uropathogenic and enteropathogenic bacteria and for their ability to co-aggregate with Candida albicans. Candidate strains for development of novel probiotic preparations were selected and will be investigated in vivo.hide news
Scientists from Lactina Ltd. attended the 26th International Symposium on Diabetes and Nutrition, Golden Sands, Varna, 26-29.06.2008, organized by the European Association for the Study of Diabetes (EASD). Results from clinical studies with probiotc Actiflora® were presented.hide news
Lactina Ltd. became member of Lactic Acid Bacteria Industrial Platform (labip.com), the Industry Platform for EU sponsored research programs on lactic acid bacteria. Representatives of the company will participate in LABIP 2008 General Assembly.hide news